Medicare Part D coverage · 24 · RxCUI 2706378
24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi]
Per the CMS 2026 Part D formulary file, 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] is covered by 115 Medicare Part D plans (2.3% of enrollable products), averaging Tier 5, with prior authorization required on 0% of covering formularies.
- 2.3%
- Plan coverage
- 115
- Plans covering
- T5
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi]
Per the CMS 2026 Part D formulary file, 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] (RxNorm concept RXCUI 2706378, generic name 24) appears on 2 distinct formulary files spanning 115 Medicare Part D plan offerings - 2.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 5 to Tier 5, with a cross-plan average of Tier 5.
Real-world access to 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] today.
Coverage Details
- Formularies covering
- 2
- Plans covering
- 115
- Coverage rate
- 2.3%
- Tier range
- Tier 5, Specialty
- Average tier
- Tier 5, Specialty
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] covered by Medicare Part D?
Yes, 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] is covered by 115 Medicare Part D plans (2.3% of all Part D formularies).
What tier is 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] on Medicare Part D plans?
24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] averages Tier 5 across Part D plans, ranging from Tier 5 to Tier 5.
Does 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] require prior authorization?
0% of Part D formularies require prior authorization for 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi]. Step therapy: 0%. Quantity limits: 0%.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 0.8 ML adalimumab-adaz 100 MG/ML Auto-Injector T5
- metronidazole 10 MG/ML Topical Cream [Noritate] T5
- 1 ML ustekinumab-ttwe 90 MG/ML Prefilled Syringe T5
- formoterol fumarate 0.01 MG/ML Inhalation Solution [Perforomist] T5
- deferiprone 1000 MG Oral Tablet [Ferriprox] T5
- ruxolitinib 15 MG/ML Topical Cream [Opzelura] T5